Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ENTPD2 | Q9Y5L3 | 2/20 | 0.34 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.33 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.33 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17198781 | 0.85 | SLC28A1 (0.39) | ENTPD2P2RY2P2RY4STING1 | |
| SCHEMBL17198789 | 0.85 | SLC28A1 (0.39) | ENTPD2P2RY2P2RY4STING1 | |
| SCHEMBL17198782 | 0.85 | SLC28A1 (0.39) | ENTPD2P2RY2P2RY4STING1 | |
| SCHEMBL17198784 | 0.85 | SLC28A1 (0.39) | ENTPD2P2RY2P2RY4STING1 | |
| SCHEMBL17198411 | 0.85 | SLC28A1 (0.39) | ENTPD2P2RY2P2RY4STING1 | |
| SCHEMBL17198783 | 0.85 | SLC28A1 (0.39) | ENTPD2P2RY2P2RY4STING1 | |
| SCHEMBL17198774 | 0.85 | SLC28A1 (0.39) | ENTPD2P2RY2P2RY4STING1 | |
| SCHEMBL25414625 | 0.81 | DHFR (0.39) | DUTCYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL31614593 | 0.81 | DHFR (0.39) | DUTCYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL18512695 | 0.76 | P2RY12 (0.36) | P2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | RB1, NSUN2, METTL3 | DUT 208/4885CYP3A4 3319/4885CYP2C9 3771/4885 |
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | RB1, NSUN2, METTL3 | DUT 201/4885CYP3A4 3291/4885CYP2C9 3724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.